Article information
Full text is only aviable in PDF
References
[1.]
F.M. Wigley.
Raynaud's phenomenon.
N Engl J Med, 347 (2002), pp. 1001-1008
[3.]
H.R. Maricq, P.H. Carpentier, M.C. Weinrich, J.E. Keil, Y. Palesch, C. Biro, et al.
Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison.
J Rheumatol, 24 (1997), pp. 879-889
[4.]
H.R. Maricq, M.C. Weinrich, J.E. Keil, E.C. LeRoy.
Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire.
J Chronic Dis, 39 (1986), pp. 423-427
[5.]
N. Olsen, S.L. Neilsen.
Prevalence of primary Raynaud's phenomenon in young females.
Scand J Clin Lab Invest, 37 (1978), pp. 761-764
[6.]
L. Fraenkel, Y. Zhang, C.E. Chaisson, H.R. Maricq, S.R. Evans, F. Brand, et al.
Different factors influencing the expression of Raynaud's phenomenon in men and women.
Arthritis Rheum, 42 (1999), pp. 306-310
[7.]
Y.Y. Palesch, I. Valter, P.H. Carpentier, H.R. Maricq.
Association between cigarette and alcohol consumption and Raynaud's phenomenon.
J Clin Epidemiol, 52 (1999), pp. 321-328
[8.]
F.K. Tan, F.C. Arnett.
Genetics factors in the etiology of systemic sclerosis and Raynaud's phenomenon.
Curr Opin Rheumatol, 12 (2000), pp. 511-519
[9.]
D.D. Gerbracht, V.D. Steen, G.L. Ziegler, T.A. Medsger, G.P. Rodnan.
Evolution of primary Raynaud’ phenomenon (Raynaud's disease) to connective tissue disease.
Arthritis Rheum, 28 (1985), pp. 87-92
[10.]
G.J. Landry, J.M. Edwards, R.B. McLafferty, L.M. Taylor Jr., J.M. Porter.
Longterm outcome of Raynaud's syndrome in a prospectively analyzed patient cohort.
J Vasc Surg, 23 (1996), pp. 76-78
[11.]
G. Spencer-Green.
Outcomes in primary Raynaud phenomenon: a metaanalysis of the frequency, rates and predictors of transition to secondary disease.
Arch Intern Med., 158 (1998), pp. 595-600
[12.]
T. Lewis.
Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation of the fingers: a variety of Raynaud's disease.
Heart, 14 (1929), pp. 7-101
[13.]
N.A. Flavahan, S. Flavahan, Q. Liu, S. Wu, W. Tidmore, C.M. Wiener, et al.
Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma.
Arthritis Rheum, 43 (2000), pp. 1886-1890
[14.]
J. Block, W. Sequeira.
Raynaud's phenomenon.
Lancet, 357 (2001), pp. 2042-2048
[15.]
F.M. Wigley, N.A. Flavahan.
Raynaud's phenomenon.
Rheum Dis Clin North Am, 22 (1996), pp. 765-781
[16.]
M.B. Kahaleh, P.S. Fan.
Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera.
Clin Immunol Immunopathol, 83 (1997), pp. 32-40
[17.]
R. Sgonc, M.S. Gruschwitz, G. Boeck, N. Sepp, J. Gruber, G. Wick.
Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cellmediated cytotoxicity via CD95.
Arthritis Rheum, 43 (2000), pp. 2550-2562
[18.]
C.B. Bunker, G. Teranghi, D.R. Springall, J.M. Polak, P.M. Dowd.
Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon.
Lancet, 336 (1990), pp. 1530-1533
[19.]
N.A. Flavahan, S. Flavahan, S. Mitra, M.A. Chotani.
The vasculopathy of Raynaud's phenomenon and scleroderma.
Rheum Dis Clin North Am, 29 (2003), pp. 275-291
[20.]
L.K. Hummers, F.M. Wigley.
Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma.
Rheum Dis Clin North Am, 29 (2003), pp. 293-313
[21.]
G.P. Rodnan, R.L. Myerowitz, G.O. Justh.
Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon.
Medicine (Baltimore), 59 (1980), pp. 393-408
[22.]
Z. Mackiewicz, A. Sukura, D. Povilenaité, A. Ceponis, I. Virtanen, M. Hukkanen, et al.
Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin.
Clin Exp Rheumatol, 20 (2002), pp. 641-646
[23.]
Y.T. Konttinen, Z. Mackiewicz, P. Ruutttila, A. Ceponis, A. Sukura, D. Povilenaité, et al.
Vascular damage and lack of angiogenesis in systemic sclerosis skin.
Clin Rheumatol, 22 (2003), pp. 196-202
[24.]
R.F. Macko, A.C. Gelber, B.A. Young, M.H. Lowitt, B. White, F.M. Wigley, et al.
Increased circulating concentrations of the counter adhesive proteins sparc and thrombospondin-1 in systemic sclerosis (scleroderma).
Relationship to platelet and endothelial cell activation. J Rheumatol, 29 (2002), pp. 2565-2570
[25.]
P.A. Merkel, K. Herlyn, R.W. Martin, J.J. Anderson, M.D. Mayes, P. Bell, et al.
Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Arthritis Rheum, 46 (2002), pp. 2410-2420
[26.]
Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud's phenomenon.
Results from randomized clinical trial with 1-year follow-up.
Arch Intern Med, 160 (2000), pp. 1101-1108
[27.]
L. Fraenkel.
Raynaud's phenomenon: epidemiology and risk factors.
Curr Rheumatol Rep, 4 (2002), pp. 123-128
[28.]
B.J. Harrison, A.J. Silman, S. Hider, A.L. Herrick.
Cigarette smoking: a risk factor for digital vascular complications in systemic sclerosis.
Arthritis Rheum, 4 (2002), pp. 3312-3316
[29.]
L. Fraenkel, Y. Zhang, C.E. Chaisson, S.R. Evans, P.W. Wilson, D.T. Felson.
The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women.
Ann Intern Med, 129 (1998), pp. 208-211
[30.]
J. Lekakis, C. Papamichel, M. Mavrikakis, A. Voutsas, S. Stamatelopoulos.
Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis.
Am J Cardiol, 82 (1998), pp. 1555-1557
[31.]
L.H. Opie.
Pharmacological differences between calcium antagonists.
Eur Heart J, 18 (1997), pp. A71-A79
[32.]
A.E. Thompson, B. Shea, V. Welch, D. Fenlon, J.E. Pope.
Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Arthritis Rheum, 44 (2001), pp. 1841-1847
[33.]
M. Rademaker, E.D. Cooke, N.E. Almond, J.A. Beacham, R.E. Smith, T.G. Mant, et al.
Comparison of intravenous infusions of iloprost. oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomized study.
BMJ, 298 (1989), pp. 561-564
[34.]
A.E. Thompson, J.E. Pope.
Calcium-channel blockers for Raynaud's phenomenon: a meta-analysis.
Rheumatology (Oxford), 44 (2005), pp. 145-150
[35.]
L. La Civita, N. Pitaro, M. Rossi, I. Gambini, D. Giuggioli, G. Cini, et al.
Amlodipine in the treatment of Raynaud's phenomenon.
Br J Rheumatol, 32 (1993), pp. 524-525
[36.]
C.G. Kallenberg, A.A. Wouda, L. Meems, H. Wesseling.
Once daily felodipine in patients with primary Raynaud's phenomenon.
Eur J Clin Pharmacol, 40 (1991), pp. 313-315
[37.]
J.F. Schmidt, N. Valentin, S.L. Nielsen.
The clinical effect of felodipine and nifedipine in Raynaud's phenomenon.
Eur J Clin Pharmacol, 37 (1989), pp. 191-192
[38.]
J. Leppert, T. Jonasson, H. Nilsson, I. Ringqvist.
The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose response study.
Cardiovasc Drugs Ther, 3 (1989), pp. 397-401
[39.]
M.G. Sturgill, J.R. Seibold.
Rational use of calcium-channel antagonists in Raynaud's phenomenon.
Curr Op Rheumatol, 10 (1998), pp. 584-588
[40.]
H. Wollersheim, T. Thien.
Double-blind placebo controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon.
J Cardiovasc Pharmacol, 18 (1991), pp. 813-818
[41.]
J. Da Costa, J.A. Gomes, J. Espirito Santo, M. Queirós.
Inefficacy of diltiazem in the treatment of Raynaud's phenomenon with associated connective tissue disease: a double blind placebo controlled study.
J Rheumatol, 14 (1987), pp. 858-859
[42.]
E.L. Kinney, G.G. Nicholas, J. Gallo, C. Pontoriero, R. Zelis.
The treatment of severe Raynaud's phenomenon with verapamil.
J Clin Pharmacol, 22 (1982), pp. 74-76
[43.]
M. Mittag, P. Beckheinrich, U.F. Haustein.
Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
Acta Derm Venereol, 81 (2001), pp. 294-297
[44.]
M.B. Kahaleh, M. Matucci Cerinic.
Fan P-S. Modulation of endothelial gene expression by prostanoids in systemic sclerosis.
Arthritis Rheum, 43 (2000), pp. S258
[45.]
J.S. Mohrland, J.M. Porter, E.A. Smith, J. Belch, M.H. Simms.
A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.
Ann Rheum Dis, 44 (1985), pp. 754-760
[46.]
P. Lamprecht, A. Schnabel, W.L. Gross.
Efficacy of alprostail and iloprost in digital necrosis due to secondary Raynaud's phenomenon.
Br J Rheumatol, 37 (1998), pp. 703-704
[47.]
B. Marasini, M. Massarottti, B. Bottasso, R. Coppola, N. Del Papa, W. Maglione, et al.
Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon.
Scan J Rheumatol, 33 (2004), pp. 253-256
[48.]
J.J. Belch, P. Newman, J.K. Drury, H. Capell, P. Leiberman, W.B. James, et al.
Successful treatment of Raynaud's syndrome with prostacyclin.
Thromb Haemost, 45 (1981), pp. 255-256
[49.]
P.M. Dowd, M.F.R. Martin, E.D. Cooke, S.A. Bow-Cock, R. Jones, P.A. Ieppe, et al.
Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).
Br J Dermatol, 106 (1982), pp. 81-89
[50.]
J.J. Belch, J.K. Drury, H. Capell, C.D. Forbes, P. Newman, F. McKenzie, et al.
Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.
Lancet, 1 (1983), pp. 313-315
[51.]
N.J. McHugh, M. Csuka, H. Watson, G. Belcher, A. Amadi, E.F. Ring, et al.
Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.
Ann Rheum Dis, 47 (1988), pp. 43-47
[52.]
D.A. Yardumian, D.A. Isenberg, M. Rustin, G. Belcher, M.L. Snaith, P.M. Dowd, et al.
Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.
Br J Rheumtol, 27 (1988), pp. 220-226
[53.]
M.V. Kyle, G. Belcher, B.L. Hazleman.
Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.
J Rheumatol, 19 (1992), pp. 1403-1406
[54.]
F.M. Wigley, J.R. Seibold, R.A. Wise, D.A. McCloskey, W.P. Dole.
Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
J Rheumatol, 19 (1992), pp. 1407-1414
[55.]
F.M. Wigley, R.A. Wise, J.R. Seibold, D.A. McCloskey, G. Kujala, T.A. Medsger.
Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, doubleblind study.
Ann Int Med, 120 (1994), pp. 199-206
[56.]
J. Pope, D. Fenlon, A. Thompson, B. Shea, D. Furst, G. Wells, et al.
Iloprost and cicaprost for Raynaud's phenomenon in progressive systemic sclerosis.
Cochrane Database Sys Rev, 1 (2005),
[57.]
J.J. Belch, H.A. Capell, E.D. Cooke, J.D. Kirby, C.S. Lau, R. Madhok, et al.
Oral iloprost as a treatment for Raynaud's syndrome: a double-blind, multicentre, placebo controlled study.
Ann Rheum Dis, 54 (1995), pp. 197-200
[58.]
C.S. Lau, J.J. Belch, R. Madhok, H. Cappell, A. Herrick, M. Jayson, et al.
A randomized, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.
Clin Exp Rheumatol, 11 (1993), pp. 35-40
[59.]
F.M. Wigley, J.H. Korn, M.E. Csuka, T.A. Medsger Jr, N.F. Rothfield, M. Ellman, et al.
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis. A multicentre, placebo-controlled, doubleblind study.
Arthritis Rheum, 41 (1998), pp. 670-677
[60.]
C.M. Black, L. Halkier Sorensen, J.J.F. Belch, S. Ullman, R. Madhik, A.J. Smith, et al.
Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
Br J Rheumatol, 37 (1998), pp. 952-960
[61.]
R.A. Wise, F. Wigley.
Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon.
J Rheumatol, 21 (1994), pp. 80-83
[62.]
M. Vayssairat.
Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes.
J Rheumatol, 23 (1996), pp. 1917-1920
[63.]
M. Rademaker, E.D. Cooke, N.E. Almond, J.A. Beacham, R.E. Smith, T.G. Mant, et al.
Comparison of intravenous infusions of iloprost. oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomized study.
BMJ, 298 (1989), pp. 561-564
[64.]
R. Scorza, M. Caronni, B. Mascagni, V. Berruti, S. Bazzi, E. Micallef, et al.
Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Clin Exp Rheumatol, 19 (2001), pp. 503-508
[65.]
P. Maddison.
Prevention of vascular damage in scleroderma with angiotensinconverting enzyme (ACE) inhibition.
Rheumatology (Oxford), 41 (2002), pp. 965-971
[66.]
M. Dziadzio, C.P. Denton, R. Smith, K. Howell, A. Blann, E. Bowers, et al.
Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
Arthritis Rheum, 42 (1999), pp. 2646-2655
[67.]
I.J. Russell, J.A. Lessard.
Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study.
J Rheumatol, 12 (1985), pp. 94-98
[68.]
R.S. Surwit, R.S. Gilgor, L.M. Allen, M. Duvic.
A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
Arch Dermatol, 120 (1984), pp. 329-331
[69.]
J. Pope, D. Fenlon, A. Thompson, B. Shea, D. Furst, G. Wells, et al.
Prazoin for Raynaud's phenomenon in progressive systemic sclerosis.
Cochrane Database Sys Rev, 1 (2005),
[70.]
R.A. Wise, F.M. Wigley, B. White, G. Leatherman, J. Zhong, H. Krasa, et al.
Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a singlecenter, double-blind, placebo-controlled, randomized crossover study.
Arthritis Rheum, 50 (2004), pp. 3994-4001
[71.]
M.E. Anderson, T.L. Moore, S. Hollis, M.I. Jayson, T.A. King, A.L. Herrick.
Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis.
Rheumatology (Oxford), 41 (2002), pp. 324-328
[72.]
C. Kan, S. Akimoto, M. Abe, K. Okada, O. Ishikawa.
Preliminary thermographic evaluation of new nitroglycerine tape on the peripheral circulatory disturbance in systemic sclerosis.
Ann Rheum Dis, 61 (2002), pp. 177-179
[73.]
R.R. Freedman, R. Girgis, M.D. Mayes.
Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma.
Lancet, 354 (1999), pp. 739
[74.]
C.M. Rembold, C.R. Ayers.
Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon.
Mol Cell Biochemi, 244 (2003), pp. 139-141
[75.]
B.K.S. Sastry, C. Narasimhan, N. Krishna Reddy, B. Soma Raju.
Clinical efficacy of sildenafil in primary pulmonary hypertension. A randomized, placebocontrolled, double-blind, crossover study.
J Am Coll Cardiol, 43 (2004), pp. 1149-1153
[76.]
G. Simonneau, G. Burgess, T. Parpia, D. Badesch.
Sildenafil improves exercise ability and hemodynamics in patients with pulmonary arterial hyper-tension associated with connective tissue disease.
Ann Rheum Dis, 64 (2005), pp. 109
[77.]
S. Rosenkranz, F. Diet, T. Karasch, J. Weinbrauc, K. Wasserman, E. Erdman.
Sildenafil improved pulmonary hypertension and peripheral blood flow in patient with scleroderma-associated lung fibrosis and Raynaud phenomenon.
Ann Int Med, 139 (2003), pp. 871-872
[78.]
J. Gore, R. Silver.
Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
Ann Rheum Dis, 64 (2005), pp. 1387
[79.]
M. Baumhaekel, P. Scheffler, M. Boehm.
Use of tadalafil in a patient with secondary Raynaud's phenomenon not responding to sildenafil.
Microvasc Res, 69 (2005), pp. 178-179
[80.]
M.D. Mayes.
Endothelin and endothelin receptor antagonists in systemic rheumatic disease.
Arthritis Rheum, 48 (2003), pp. 1190-1199
[81.]
M. Ramos-Casals, P. Brito-Zeron, N. Nardi, G. Claver, G. Risco, F.D. Parraga, et al.
Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis.
Rheumatology (Oxford), 43 (2004), pp. 1454-1456
[82.]
J.H. Korn, M. Mayes, M. Matucci-Cerinic, M. Rainisio, J. Pope, E. Hachulla, RAPIDS-1 Study Group, et al.
Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Arthritis Rheum, 50 (2004), pp. 3985-3993
[83.]
B. Coleiro, S.E. Marshall, C.P. Denton, K. Howell, A. Blann, K.I. Welsh, et al.
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
Rheumatology (Oxford), 40 (2001), pp. 1038-1043
[84.]
J. Pope, D. Fenlon, A. Thompson, B. Shea, D. Furst, G. Wells, et al.
Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.
Cochrane Database Sys Rev, (2005),
[85.]
C.B. Bunker, C. Reavley, D. O'Shaughnessy, P.M. Dowd.
Calcitonin generelated peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon.
Lancet, 342 (1993), pp. 80-82
[86.]
V.L. Beckett, D.L. Conn, V. Fuster, P.J. Osmundson, C.G. Strong, E.Y. Chao, et al.
Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin.
Arthritis Rheum, 27 (1984), pp. 1137-1143
[87.]
J. van der Meer, A.A. Wouda, C.G. Kallenberg, H. Wesseling.
A doubleblind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud's phenomenon.
Vasa Suppl, 18 (1987), pp. 71-75
[88.]
C.P. Denton, K. Howell, R.J. Stratton, C.M. Black.
Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study.
Clin Exp Rheumatol, 18 (2000), pp. 499-502
[90.]
S. Rajagopalan, D. Pfenninger, E. Somers, C. Kehrer, A. Chakrabarti, D. Mukherjee, et al.
Effects of cilostazol in patients with Raynaud's syndrome.
Am J Cardiol, 92 (2003), pp. 1310-1315
[91.]
A.L. Herrick, M. Matucci Cerinic.
The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis.
Clin Exp Rheumatol, 19 (2001), pp. 4-8
[92.]
A.L. Herrick.
Treatment of Raynaud's phenomenon: new insights and developments.
Curr Rheumatol Rep, 5 (2003), pp. 168-174
[93.]
C.P. Denton, T.D. Bunce, M.B. Darado, Z. Roberts, H. Wilson, K. Howell, et al.
Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon.
Rheumatology (Oxford), 38 (1999), pp. 309-315
[94.]
A.L. Herrick, S. Hollis, D. Schofield, F. Rieley, A. Blann, K. Griffin, et al.
A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis.
Clin Exp Rheumatol, 18 (2000), pp. 349-356
[95.]
M.E. Mavrikakis, J.P. Lekakis, C.M. Papamichael, K.S. Stamatelopoulos, Ch.C. Kostopoulos, S.F. Stamatelopoulos.
Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Int J Vitam Nutr Res, 73 (2003), pp. 3-7
[96.]
J.P. Johnson, C. Obasi, M.S. Hahn, P. Glatleider.
Endoscopic thoracic sympathectomy.
J Neurosurg Spine, 91 (1999), pp. 90-97
[97.]
J.C. de Trafford, K. Lafferty, C.E. Potter, V.C. Roberts, L.T. Cotton.
An epidemiological survey of Raynaud's phenomenon.
Eur J Vasc Surg, 2 (1988), pp. 167-170
[98.]
A.E. Flatt.
Digital artery sympathectomy.
J Hand Surg, 5 (1980), pp. 550-556
Copyright © 2008. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
